← Evidence map

ReviewCureus2025

Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2).

Abdulkreem Al-Juhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). | Socratic